Transaction in Own Shares
Updated : 07:02
Burberry Group plc
Transaction in own shares
Burberry Group plc ("Burberry") announces that on 14 September 2018 it purchased the following number of its ordinary shares of 0.05 pence each on the London Stock Exchange from Merrill Lynch International. Such purchase was effected pursuant to instructions issued by Burberry on 21 June 2018, as announced on 22 June 2018:
Ordinary Shares
Date of purchase | 14 September 2018 |
Number of ordinary shares purchased: | 324,262 |
Highest price paid per share (pence): | 2160.00 |
Lowest price paid per share (pence): | 2102.00 |
Average price paid per share (pence): | 2129.75 |
Burberry intends to hold the purchased shares in treasury.
Following the above transaction, Burberry holds 6,663,764 of its ordinary shares in treasury and has 411,674,483 ordinary shares in issue (excluding treasury shares).
Therefore, the total number of voting rights in the Company will be 411,674,483 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
A full breakdown of the individual trades is attached to this announcement.
http://www.rns-pdf.londonstockexchange.com/rns/8841A_1-2018-9-14.pdf
This announcement does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any Burberry Group plc shares, in the UK, or in the US, or under the US Securities Act 1933 or in any other jurisdiction.
Burberry is listed on the London Stock Exchange (BRBY.L) and is a constituent of the FTSE 100 index. ADR symbol OTC:BURBY.
BURBERRY, the Equestrian Knight Device and the Burberry Check are trademarks belonging to Burberry which are registered and enforced worldwide.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.